C3 and cold agglutinin disease: Building on promising off-label reports from individual case studies (162–164), the phase 2 DECADE trial, conducted in 13 CAD patients, demonstrated a reduction in transfusion requirements, although the median hemoglobin increase remained modest, likely due to persistent C3b-mediated opsonization and ongoing extravascular hemolysis (152).